Perrigo CEO Takes Faith In Rx Generics Business To Exit Door With Him
Executive Summary
Private label OTC business is likely to be strengthened as Perrigo’s core, as CEO Hendrickson announces retirement shortly after hedge fund investor Starboard Value, pushing to divest the Rx business, built a five-seat block on Perrigo's board.
You may also be interested in...
Perrigo Expanding Consumer Portfolio After Finding Problems Slowing Growth
"Probably the worst offense" among Perrigo's problems is that before appointing President and CEO Murray Kessler in November, it had three CEOs since 2016, making him the fourth chief executive in three years, says Kessler. Perrigo's move to a self-care focus means "a broader emphasis on the wellness component of health and wellness" and opening its portfolio of products and categories to areas including nutraceuticals, oral care, probiotics, therapeutic skin care products and others.
Another Change At Perrigo Helm As Results Remain Turbulent
Incoming CEO Murray Kessler is a seasoned veteran of regulated consumer markets – but not health care. Will his combination of experience and fresh perspective help enable the OTC private label market leader to reverse share declines?
Another Change At Perrigo Helm As Results Remain Turbulent
Incoming CEO Murray Kessler is a seasoned veteran of regulated consumer markets – but not health care. Will his combination of experience and fresh perspective help enable the OTC private label market leader to reverse share declines?